Clinical Oncology
Volume 22, Issue 2 , Pages 91-96 , March 2010

A Study of Medical Intervention in Routine Breast Cancer Follow-up

  • Q. Ghafoor

      Affiliations

    • Cancer Centre, University Hospital Coventry and Warwick, Coventry, UK
    • ,
  • P. Sanghera

      Affiliations

    • Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
    • ,
  • R.J. Grieve

      Affiliations

    • Cancer Centre, University Hospital Coventry and Warwick, Coventry, UK
    • Corresponding Author InformationAuthor for correspondence: R. J. Grieve, Cancer Centre, University Hospital Coventry and Warwick, Coventry CV2 2DX, UK. Tel: +44-2476-967153; Fax: +44-2476-967474.

Received 18 August 2009 ,Revised 18 November 2009 ,Accepted 19 November 2009.

References 

  1. Office for National Statistics . Cancer statistics registrations: registrations of cancer diagnosed in 2004, England. Series MB1 no. 35 London: Office for National Statistics; 2007;
  2. NHS Scotland . ISD online. Information and Statistics Division, NHS Scotland; 2007;Available from: http://www.isdscotland.org/isd/6080.html
  3. Welsh Cancer Intelligence and Surveillance Unit . Cancer incidence in Wales. Welsh Cancer Intelligence and Surveillance Unit; 2007;Available from: http://www.wales.nhs.uk/sites3/Documents/242/incpub2006_31Jan08.pdf
  4. Micheli A, Mugno E, Krogh V, et al., EUROPREVAL Working Group  Cancer prevalence in European registry areas. Ann Oncol. 2002;13(6):815–816
  5. Office for National Statistics. Long term breast cancer survival, England and Wales, up to 2003. London: Office for National Statistics. Available from: http://www.statistics.gov.uk/STATBASE/ssdataset.asp?vlnk=9132&More=Y; 2005.
  6. Grunfeld E, Gray A, Mant D, et al. Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer. 1999;79(7–8):1227–1233
  7. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006;24(6):848–855
  8. Donnelly P, Hiller L, Bathers S, et al. Questioning specialists' attitudes to breast cancer follow-up in primary care. Ann Oncol. 2007;18(9):1467–1476
  9. National Institute for Health and Clinical Excellence . NICE guidance. CG80 early and locally advanced breast cancer: full guideline. Available from: http://guidance.nice.org.uk/CG80/Guidance/pdf/English29 May 2009;
  10. Forbes JF, Cuzick J, Buzdar A, et al., Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53
  11. Thürlimann B, Keshaviah A, Coates AS, et al., Breast International Group (BIG) 1-98 Collaborative Group  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757
  12. Coombes RC, Hall E, Gibson LJ, et al., Intergroup Exemestane Study  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–1092
  13. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–1802
  14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672
  15. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol. 2007;25(18S):512
  16. Romond E, Perez EA, Bryant J, et al. Joint analysis of NSAPB-B-31 and NCCTG-N9831. Presented at ASCO Annual Meeting, Orlando, 2005. Available from: http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?vmview=vm_session_presentations_view&confID=34&sessionID=934.
  17. BBC trial information . NCRN database. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1620
  18. Gray RG, Rea DW, Handley K, et al. aTTom (adjuvant Tamoxifen–To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer–preliminary results. J Clin Oncol. 2008;26(Suppl.):abstract 513
  19. Burkinshaw R, Thorpe H, Pollard S, et al. The AZURE trial – does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?. Bone. 2006;38(3; Suppl. 1):70–71
  20. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851–1862
  21. The pharmacogenetics of early breast cancer chemotherapy. Available from: http://www.cancerhelp.org.uk/trials/trials/trial.asp?=&trialno=15184
  22. Eccles D, Gerty S, Simmonds P, et al. Prospective study of outcomes of treatment in hereditary versus sporadic breast cancer. BMC Cancer. 2007;7:160
  23. Prescott RJ, Kunkler IH, Williams LJ, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess. 2007;11(31):1–149iii–iv
  24. Randomised European Celecoxib Trial. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1238.
  25. Sequencing of chemotherapy and radiotherapy in adjuvant breast cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00003893
  26. Prospective randomised comparison of G-CSF (filgrastim) secondary prophylaxis versus conservative management of chemotherapy-induced neutropenia to maintain dose intensity in chemotherapy for breast cancer. Available from: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1178
  27. Ellis P, Barrett-Lee P, Johnson L, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009;373(9676):1681–1692
  28. An open label, randomised, multicentre, comparative trial of 5 years adjuvant exemestane treatment versus adjuvant tamoxifen followed by exemestane in postmenopausal women with early breast cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00032136
  29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Available from: http://www.ctsu.ox.ac.uk/projects/ebctcg.
  30. Tomiak E, Piccart M. Routine follow-up of patients after primary therapy for early breast cancer: changing concepts and challenges for the future. Ann Oncol. 1993;4:199–204
  31. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000;92:1054–1064
  32. Yarnold J. Early and locally advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence guideline 2009. Clin Oncol. 2009;21(3):159–160
  33. Grunfeld E, Dhesy-Thind S, Levine MN. Follow-up after treatment for breast cancer (summary of the 2005 update). Can Med Assoc J. 2005;172:1319–1320
  34. Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. Br Med J. 1996;313(7058):665–669
  35. Lewis RA, Neal RD, Williams NH, et al. Follow-up of cancer in primary care versus secondary care: systematic review. Br J Gen Pract. 2009;59(564):e234–e247
  36. Baildam AD, Keeling F, Thompson L, Bundred N, Hopwood P. Nurse-led surgical follow up clinics for women treated for breast cancer – a randomised controlled trial. Breast Cancer Res Treat. 2004;88:S136–S137
  37. Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structured review. Cancer Treat Rev. 2004;30:19–35
  38. Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer. 2007;96:1625–1632
  39. Guidance for the management of breast cancer treatment-induced bone loss. Available from: http://www.nos.org.uk/NetCommunity/Document.Doc?id=124
  40. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer. 1989;63(10):1912–1917
  41. Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48(5):1281–1289
  42. Chapman D, Cox E, Britton PD, et al. Patient-led breast cancer follow up. Breast. 2009;18(2):100–102

PII: S0936-6555(09)00378-1

doi: 10.1016/j.clon.2009.11.008

Clinical Oncology
Volume 22, Issue 2 , Pages 91-96 , March 2010

Article Tools

* Image Usage & Resolution